The Atriva Approach

ATRIVA is changing the philosophy and strategy of antiviral drug development. Instead of targeting the virus directly, the ATRIVA compounds are directed against a cellular factor of the host cell. In order to ensure efficient replication, the virus needs to activate this factor. ATRIVA’s lead compound ATR-002 prevents the virus-induced activation of the cellular factor and consequently viral replication.

Approach Virus

Various viruses need to activate this cellular factor for replication, including viruses responsible for respiratory tract infections. Thus, ATR-002 might not only be effective against influenza virus but also against others viruses that cause influenza like illness (ILI). Consequently, ATR-002 will be developed as the first-in-class compound against influenza- and other respiratory viruses. 

 

 

Indications

ATRIVA aims to develop antiviral therapies against severe respiratory viral infections.

Great potential against influenza virus and potentially corona viruses due to antiviral and immunomodulating activity of ATRIVA’s lead product ATR-002. Phase I clinical trial successfully completed, Phase II under preparation.

 

 

Pipeline 

 

 


 

For detail and further readings:

Pleschka et al. 2001; Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade Nature Cell Biology 3:301–305.

Droebner et al. 2011; Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo. Antiviral Research 92:195-203.

Planz 2013; Development of cellular signaling pathway inhibitors as new antivirals against influenza. Antiviral Research 98:457-468

PHaasbach et al 2017; The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo. Antiviral Research 142:178-184.

Address

Atriva Therapeutics GmbH
Christophstr. 32, 72072 Tübingen

+49 (0)7071 8597673
info@atriva-therapeutics.com

LinkedIn
Twitter

In order to be able to design our website in the best possible way and to continuously improve it, we are using cookies. By continuing to use our website, you permit the use of cookies. More information can be found in our data protection rules.